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NONSTANDARD ABBREVIATIONS
ACC acetyl-CoA carboxylase
AKT protein kinase B
AMPK AMP-activated protein kinase
AS160 Akt substrate of 160 kDa
CaMKK calcium/calmodulin-dependent protein kinase kinase
CHI3L1 chitinase-3-like protein 1
DM diabetes
DMEM Dulbecco's modified Eagle's medium
EPS electrical pulse stimulation
GLUAUC glucose response area
GLUT4 glucose transporter type 4
GPCR G-protein-coupled receptor
GTT glucose tolerance test
HRP horseradish peroxidase
IGT impaired glucose tolerance
IL interleukin
LCL lymphoblastoid cell lines
MAPK mitogen-activated protein kinase
NGT normal glucose tolerance
PAR2 proteinase-activated receptor 2




TNFα tumor necrosis factor-α
ABSTRACT
We investigated the effect of chitinase-3-like protein 1 (CHI3L1) on glucose metabolism and its underlying 
mechanisms in skeletal muscle cells, and evaluated whether the observed effects are relevant in humans. 
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with increased intracellular calcium levels via PAR2. The improvement in glucose metabolism observed in an 
intraperitoneal glucose tolerance test on male C57BL/6J mice supported this association. Inhibition of the 
CaMKK was associated with suppression of CHI3L1-mediated glucose uptake. Additionally, CHI3L1 was 
found to influence glucose uptake through the PI3K/AKT pathway. Results suggested that CHI3L1 stimulated 
the phosphorylation of AS160 and p38 MAPK downstream of AMPK and AKT, and the resultant GLUT4 
translocation. In primary myoblast cells, stimulation of AMPK and AKT was observed in response to CHI3L1, 
underscoring the biological relevance of CHI3L1. CHI3L1 levels were elevated in cells under conditions that 
mimic exercise in vitro and in exercised mice in vivo, indicating that CHI3L1 is secreted during muscle 
contraction. Finally, similar associations between CHI3L1 and metabolic parameters were observed in humans 
alongside genotype associations between CHI3L1 and diabetes at the population level. CHI3L1 may be a 
potential therapeutic target for the treatment of diabetes.
Keywords: Chitinase-3-like protein 1, glucose metabolism, AMPK, myokine, glucose uptake
INTRODUCTION
Skeletal muscle has been identified as a secretory organ (1), that produces, expresses, and releases myokines 
and other cytokines by exercising muscle fibers (2, 3). Myokines consist of muscle-secreted cytokines that 
communicate with other organs, including adipose tissue, liver, brain, and immune system, in an autocrine, 
paracrine, or endocrine manner (4), which has been proposed to mediate the beneficial effects of exercise in 
regulating whole-body metabolism and treating metabolic diseases.
Chitinase 3-like protein 1 (CHI3L1), also known as YKL-40, was originally identified in mouse breast cancer 
cells (5). It is a secreted heparin- and chitin-binding glycoprotein that lacks chitinase activity (6, 7) and is 
expressed by many different cell types, including neutrophils, macrophages, osteoclasts, chondrocytes, 
fibroblasts, vascular smooth muscle cells, endothelial cells, and skeletal muscle cells (8, 9). CHI3L1 expression 
is regulated by many different pro-inflammatory cytokines, including interleukin 6 (IL-6), IL-13, interferon-γ, 
IL-1β, and tumor necrosis factor-α (TNFα) (10). While CHI3L1 is predominantly associated with inflammation 
and tissue remodeling (10), recent evidence suggests that circulating CHI3L1 levels are elevated in patients with 
metabolic diseases related to insulin resistance, such as type 2 diabetes and obesity (11, 12). However, the 
molecular mechanisms and activity of CHI3L1 in these processes remain unclear. A recent report classified 
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CHI3L1 influences glucose metabolism and which intracellular signaling pathways in skeletal muscle cells 
might be involved therein.
In the present study, we evaluated CHI3L1 activity during glucose uptake and explored potential underlying 
mechanisms responsible for its effects. Our results indicate that CHI3L1 stimulates glucose uptake in skeletal 
muscles via the AMP-activated protein kinase (AMPK) and protein kinase B (AKT) signaling pathways through 
proteinase-activated receptor 2 (PAR2). We also observed that CHI3L1 levels were elevated under conditions 
that mimic exercise in vitro and in exercised mice in vivo. We then investigated whether CHI3L1 regulation of 
glucose metabolism is transferrable to humans by evaluating the associations among plasma CHI3L1 levels, 
CHI3L1 genetic variants, and lymphocytic CHI3L1 mRNA expression in humans.
MATERIALS AND METHODS
Reagents
Antibodies against the following proteins were used in this study: phospho-AMPKα (Thr172), acetyl-Coa 
carboxylase (ACC), phospho-ACC (Ser79), and Akt substrate of 160 kDa (AS160) (Millipore-Upstate, Billerica, 
MA, USA); AMPKα, AKT, phospho-AKT (Ser473), phospho-AS160 (Thr642), and p38 mitogen-activated 
protein kinase (MAPK) (Cell Signaling Technology, Beverly, MA, USA); phospho-p38 MAPK (Santa Cruz 
Biotechnology, Dallas, TX, USA); glucose transporter type 4 (GLUT4) and anti-insulin receptor (Abcam, 
Cambridge, UK); and β-actin (Enogene, New York, NY, USA). Horseradish peroxidase (HRP)-conjugated 
secondary antibodies were obtained from Enzo Life Sciences (Farmingdale, MA, USA). Compound C and 
STO-609 were obtained from Calbiochem (San Diego, CA, USA); insulin, LY294002, and thapsigargin were 
obtained from Sigma-Aldrich (St. Louis, MO, USA); U73122 and SB203580 were obtained from Abcam; and 
FSLLRY-NH2 was obtained from Tocris (Bristol, UK). CHI3L1 was purchased from Cusabio (Wuhan, Hubei, 
China). The fluorescent Ca2+ indicator Fluo-3 AM was procured from Invitrogen (Leiden, Netherlands).
Plasma membrane fractionation
A plasma membrane protein extraction kit (Abcam, Cambridge, UK) was used to obtain plasma membrane 
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Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA)/phosphate buffered saline (PBS) and permeabilized with 
0.2% Triton-X 100. After blocking with 0.2% bovine serum albumin for 30 min, the cells were incubated with 
anti-GLUT4 antibody at 1:500 dilution for 60 min and then probed with cyanine dye Cy3-labeled secondary 
antibody (Molecular Probe, Eugene, OR, USA). Stained cells were visualized on a Zeiss confocal microscope.
Immunodetection of Myc-GLUT4
Cell surface expression of Myc-GLUT4 was quantified using an antibody-coupled colorimetric absorbance 
assay. Following stimulation, myoblasts stably expressing Myc-GLUT4 were incubated with a polyclonal anti-
Myc antibody (1:1000) for 60 min, fixed with 4% PFA in PBS for 10 min, and then incubated with HRP-
conjugated goat anti-rabbit IgG (1:1000) for 1 h. The cells were washed six times with PBS and incubated in 1 
mL of o-phenylenediamine reagent (0.4 mg/mL) for 30 min. Absorbances of the supernatant were measured at 
492 nm.
Cell culture
L6 rat myoblast cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) 
supplemented with 10% fetal bovine serum and 1% antibiotics at 37 °C in a 5% CO2 atmosphere.
Measurement of 2-deoxy-d(H3)-glucose uptake
Two days after cells reached confluence, myotube differentiation was induced by incubation in DMEM 
supplemented with 2% fetal bovine serum for 6–7 days, with a change of media every 2 days. The cells were 
washed twice with PBS and then starved in serum-free low-glucose DMEM for 3 h. The cells were then 
incubated with Krebs Ringer bicarbonate (20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid 
(HEPES) [pH 7.4], 130 mM NaCl, 1.4 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, and 1.2 mM KH2PO4) followed 
by incubation with test compounds in the same buffer at 37 °C. The uptake assay was initiated by adding 2-
deoxy-d(H3)-glucose to each well and incubating at 37 °C for 15 min. The assay was terminated by washing 
with ice-cold PBS. The cells were lysed in 10% sodium dodecyl sulfate (SDS) and mixed with a scintillation 
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Immunoblotting analysis
Cells in 6-well plates were washed twice with ice-cold PBS and lysed in 70 µL lysis buffer. The samples were 
sonicated, centrifuged for 20 min, and then heated to 95 °C for 5 min. Supernatants were resolved on 10% SDS-
polyacrylamide gels and transferred to nitrocellulose membranes, which were then incubated overnight at 4 °C 
with primary antibodies. After six washes in tris-buffered saline with 0.1% Tween 20, the membranes were 
incubated with HRP-conjugated secondary antibodies at room temperature (RT) for 1 h. The blots were washed 
and visualized by chemiluminescence using an enhanced chemiluminescence Western Blot Detection System 
(Amersham International PLC, Buckinghamshire, UK).
Small interfering RNA (siRNA) transfection
Transient transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. Briefly, siRNAs targeting AMPKα2 (L-100623-02; Dharmacon, Lafayette, CO, USA) and AKT2 (L-
091136-02; Dharmacon) and a non-targeted control siRNA (D-001810-10, Dharmacon) were generated. 
siRNAs (5 µL) and Lipofectamine 2000 were each diluted with 95 µL of Opti-MEM Reduced-Serum Medium 
(Invitrogen) and then combined. The resulting mixtures were incubated at RT for 30 min before being added 
dropwise to culture wells containing 800 µL of Opti-MEM for a final siRNA concentration of 100 nM.
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed at 55 °C for 20 min using a Thermoscript II One-Step RT-PCR Kit (Invitrogen). cDNA 
amplification was performed using a GeneAmp PCR System 9700 thermocycler (Applied Biosystems, 
Warrington, UK). Reverse transcriptase was heat-inactivated in the first step of PCR (95 °C for 10 min). The 
following primers were used for amplification: CHI3L1, 5′-ATGTGGACTATGGTGTGGGG-3′ (sense) and 5′-
TGAGCGGGAAGTGTACGTTA-3′ (antisense); ACTB, 5′-ATTTGGTCGTATTGGGCGCCTGGTCACC-3′ 
(sense) and 5′-GAAGATGGTGATGGGATTTC-3′ (antisense); PAR1, 5′-GGGCAGGGCAGTCTACTTAA-3′ 
(sense) and 5′-ATGAGCATGATGGAGGCGTA-3′ (antisense); PAR2, 5′-CCAGCCTTGAACATCACCAC-3′ 
(sense) and 5′-ACAAAGGGGTCTATGCAGCT (antisense); PAR3, 5′-TGTATGGGCATCAACCGCTA-3′ 
(sense) and 5′-GGGCAAAGCAGATGGTGAAA-3′ (antisense); and PAR4, 5′-
GTCTTGCCACTCACGTTTCA-3′ (sense) and 5′-AGGGTCTACGCAGCTGTTAA-3′ (antisense). The 
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PAR3, and PAR4) or 55 °C (PAR2) for 30 sec; and at 72 °C for 30 sec, followed by 10 min at 72 °C. A 10 µL 
sample of each reaction was analyzed by agarose gel electrophoresis.
Intracellular calcium measurement using Fluo-3 AM
Cells were loaded with 5 µM Fluo-3 AM and incubated at 37 °C for 30 min. Following washing with medium, 
DMEM, or calcium-free DMEM (Thermo Fisher Scientific, Waltham, MA, USA) was added to the wells and 
the cells were observed using a confocal microscope (Zeiss LSM 510 Meta; Zeiss, Oberkochen, Germany) 
under 200× magnification on a temperature-controlled stage. Excitation and emission wavelengths for signal 
detection were 488 and 515 nm, respectively.
Primary myoblast preparation
Primary myoblasts were obtained from the forelimbs and hindlimbs of three or four 5-day-old littermate pups. 
The dissected and minced muscle samples were enzymatically disaggregated in 4 mL of PBS containing 1.5 
U/mL dispase II and 1.4 U/mL collagenase D (Roche, Penzberg, Germany) at 37 °C and were triturated with a 
10-mL pipette every 5 min for 20 min. The cells were then filtered through a 70-µm mesh (BD Biosciences, 
Seoul, Korea) and collected by centrifugation at 1,000 rpm for 5 min. The cell pellet was dissolved in 10 mL of 
F10 medium (Invitrogen) supplemented with 10 ng/mL basic fibroblast growth factor (PeproTech, Princeton, 
NJ, USA) and 10% cosmic calf serum (Hyclone, Logan, UT, USA). Finally, the cells were pre-plated twice 
onto non-collagen-coated plates for 1 h each to deplete the fibroblasts. Differentiation was induced by culturing 
primary myoblasts in DMEM containing antibiotics and 5% horse serum (Invitrogen).
Electrical pulse stimulation (EPS)
To mimic the effect of exercise in in vitro model, EPS was applied to cells to induce muscle contraction using a 
C-Pace EP culture pacer (IonOptix, Westwood, MA, USA), a multi-channel stimulator designed for the chronic 
stimulation of bulk quantities of cells in culture. This instrument emits bipolar pulses to culture media via 
immersed carbon electrodes in a C-dish. EPS was applied to L6 cells cultured in high-density micro-mass (2 × 
105 cells/mL) conditions under electrical fields of 25 V/cm, with a duration of 5 m/s and a frequency of 1 Hz. 
At appropriate time points, the cells were harvested either in TRIzol reagent (Invitrogen) for PCR analysis or in 
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Exercise session and intraperitoneal glucose tolerance test (GTT) in animals
After acclimatization for 1 week, twenty 10-week-old, specific-pathogen-free, male ICR mice (24–28 g; 
Koatech, Gyeonggido, Korea) were randomly divided into two groups: the control (n = 10) and exercise group 
(n = 10). Mice in the exercise groups were forced to perform exercise at a 10 m/min velocity for 60 min at a 
time using a motorized running wheel (20 cm diameter by 5 cm width; Shandong Yiyuan Technology 
Development Co., Shandong, Binzhou, China) for a day. The mice were sacrificed, and the plasma was 
collected for ELISA testing (MyBioSource, San Diego, USA). Their quadriceps femoris muscle was further 
prepared for biochemical analysis. The protocols were approved by the Institutional Animal Care and Use 
Committee of Korea University (Korea-2016-0252) and were conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.We examined the 
effect of CHI3L1 on glucose metabolism in vivo by conducting a metabolic GTT study in a high-fat diet (HFD)-
induced obese mouse model. Five-week-old male mice were purchased from Central Lab Animal Inc. (Seoul, 
Korea) and were maintained in accordance with the guidelines of the Institutional Animal Care and Use 
Committee of Korea University (KUIACUC-2018-63, KUIACUC-2018-0008). Mice were housed at 18–24 °C 
with a 12/12 h light/dark cycle, fed HFD ad libitum, and allowed unlimited access to water. A GTT was 
performed on two randomly assigned groups as a PBS injection (n = 8) or CHI3L1 injection (n = 8). Briefly, 
mice were fasted overnight (16 h), and a fixed dose of CHI3L1 (5 mg/kg body weight) or PBS followed by 
glucose (1 g/kg in PBS) was administered. Blood glucose levels were measured in tail vein blood with a 
glucometer (Accu-Check, Roche, Germany) at 0, 15, 30, 60, 90, and 120 min post-injection.
Association between plasma levels of CHI3L1 and diabetic status in humans
The associations of blood CHI3L1 levels with anthropometric and metabolic parameters in humans were tested 
using datasets in a clinical setting (n = 80). Plasma levels of CHI3L1 were determined by ELISA immunoassay 
(CHI3L1 ELISA kit; FineTest). The study participants were divided into four groups based on age and diabetes 
status as follows: young-normal glucose tolerance (NGT; aged 25–35 years, n = 20), old NGT (aged 65–87 
years, n = 20), old-impaired glucose tolerance (IGT; aged 65–88 years, n = 20), and old-diabetes (DM; aged 
65–89 years, n = 20). IGT was defined by 2-hour plasma glucose levels 140–199 mg/dL (14), and DM was 
defined as fasting glucose of at least 126 mg/dL and/or hemoglobin A1c of at least 6.5%, or treatment with 
antidiabetic medication. All study participants provided written informed consent before starting the 
experiments. This study was approved by the Institutional Review Board (IRB) of Seoul National University 
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amendments.
Genetic association between CHI3L1 and the risk of diabetes in humans
Genetic associations between a genetic variant of CHI3L1 and incidence of DM and related parameters were 
assessed using the Korean Genome and Epidemiology Study: Ansan and Ansung (KoGES-ASAS) in a 
community setting. The KoGES-ASAS study is described in detail elsewhere (15). The baseline survey of 
KoGES-ASAS was initiated in 2001–2002 with a total of 10,030 participants aged 40–69 years from the Ansan 
and Ansung areas of South Korea, and follow-up studies were performed every two years. Among the 10,030 
participants, 7,820 were included in this study after removing 1,190 for whom genotype data was missing, and 
1,020 participants diagnosed with DM, cardiovascular disease, or cancer at baseline. Demographic information 
on the participants, including sex, age, area, education level, smoking, drinking, and physical activity measured 
by metabolic equivalents were obtained from a questionnaire survey at each follow-up. Following 75 g oral 
GTT at baseline, plasma glucose levels were measured at 0, 60, and 120 min, and glucose response area 
(GLUAUC, mg/dL*h) was calculated. New-onset DM was defined by at least one of the following criteria: self-
reported doctor-diagnosed DM, fasting glucose level of at least 126 mg/dL, 120 min glucose levels of at least 
200 mg/dL, or taking anti-diabetic medication. Detailed information on genotyping was previously reported 
elsewhere (16). Briefly, genomic DNA was isolated from the peripheral blood of the participants, genotyped on 
an Affymetrix Genome-Wide Human SNP Array 5.0 (Affymetrix, Inc., Santa Clara, CA, USA), and imputed 
using the 1000 Genomes Phase I Integrated Release Version 3 as a reference panel. In the present study, 
rs10399805 (CHI3L1), reported to be responsible for most of the genetic effects on CHI3L1 production, was 
used in the analysis for testing associations thereof with diabetic traits (17, 18). All study participants provided 
written informed consent before starting the experiments. This study was approved by the IRB of the Korea 
Centers for Disease Control and Prevention (KBP-2018-039) and the IRB of Korea University (KUIRB-2018-
0041-01). Associations between CHI3L1 mRNA expression level and diabetic traits were assessed by obtaining 
lymphoblastoid cell lines (LCLs) from 150 individuals from a subgroup of the KoGES-ASAS (KUIRB-2018-
0041-01). 
For Reverse transcription quantitative PCR, total RNA was extracted from LCLs using the RNeasy Lipid Tissue 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. For Reverse transcription, 1µg 
of total RNA was reverse transcribed using oligo-dT SuperscriptTM II reverse transcriptase (Invitrogen). 
Quantitative PCR was performed under the following conditions: 15 min at 95 °C, followed by 40 cycles of 30 
sec at 94 °C, 30 sec at 50–60 °C, and 30 sec at 72 °C. The obtained data were analyzed using the comparative 
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primer sequences were as follows: CHI3L1, 5'-AATGGCGGTACTGACTTGATG-3' (forward) and 5'-
GAAGACTCTCTTGTCTGTCGGA-3' (reverse); and GAPDH, 5'-AACTTTGGCATTGTGGAAGG-3' 
(forward) and 5'-ACACATTGGGGGTAGGAACA-3' (reverse). Lastly, 134 individuals with LCL samples 
available for experiments were divided into four groups based on CHI3L1 mRNA expression level (divided by a 
median, low vs. high) and physical activity (divided by metabolic equivalent median, active vs. inactive) to 
examine potential mediating effects of physical activity on the association between CHI3L1 mRNA expression 
and diabetic traits. The physically active with higher CHI3L1 mRNA expression group (n = 31) and physically 
inactive with lower CHI3L1 mRNA expression (n = 32) group were directly compared.
Statistical analysis
Results for the experiments on cell systems and animals are presented as mean ± standard error of the mean 
(SEM), and differences among the experimental groups were analyzed using Student’s t-test or oneway analysis 
of variance (ANOVA) followed by Bonferroni post-test. Statistical analyses of human studies were performed 
using the Stata SE 13.0 (Stata, College Station, TX, USA) and GraphPad Prism 5.0 (GraphPad Software, Inc., 
San Diego, CA, USA) software packages. GLUAUC values were log-transformed to mimic normal distribution. 
Comparisons of plasma CHI3L1 levels, CHI3L1 mRNA expression levels, and GLUAUC levels among groups 
were performed using Student’s t-test and results are presented as mean ± SEM. The genetic effect of 
rs10399805 (CHI3L1) on the incidence of diabetes and GLUAUC levels were conducted using the Cox 
proportional hazard regression, and multiple linear regression models, respectively. Genetic associations were 
examined under a dominant model (GG vs. GA+AA) after adjusting for potential confounders, including sex, 
age, area, education level, smoking, drinking, hypertension, and metabolic equivalents, and results are presented 
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RESULTS
CHI3L1 stimulates glucose uptake via AMPK in skeletal muscle cells
Skeletal muscle is an important organ for glucose homeostasis because it induces glucose uptake to help 
maintain normal glucose levels (19). We performed a glucose uptake assay to investigate the role of CHI3L1 in 
glucose homeostasis, and found that CHI3L1 treatment of L6 cells was associated with time- (Fig. 1A) and 
dose- (Fig. 1B) dependent increases in glucose uptake. CHI3L1 was shown to induce a greater amount of 
glucose uptake than insulin, used as a positive control (Fig. 1C). We evaluated the phosphorylation of AMPK, a 
key molecule involved in glucose uptake, to identify molecular mechanisms through which CHI3L1 affects 
glucose uptake. CHI3L1 treatment of L6 cells induced phosphorylation of AMPK and its downstream molecule, 
ACC, in a time- (Fig. 1D) and dose- (Fig. 1E) dependent manner. This effect was blocked by the AMPK 
inhibitor, Compound C (Fig. 1F). Consistent with this result, the inhibition of AMPK was associated with 
suppressed CHI3L1-mediated glucose uptake (Fig. 1G). Since compound C potentially inhibits other kinases 
than AMPK, we then used siRNA to specifically knockdown AMPKα2 expression in L6 cells (Fig.1H) and 
observed that CHI3L1-induced glucose uptake was blocked by siRNA-mediated knockdown of AMPKα2 (Fig. 
1I). These results suggest that CHI3L1 stimulates glucose uptake via AMPK in skeletal muscle cells. In line 
with these findings, we also observed that intraperitoneal injection of 5 mg/kg CHI3L1 improved glucose 
metabolism, as measured by GTT and glucose response area (Fig. 1J), in mice.
CHI3L1 stimulates GLUT4 translocation in skeletal muscle cells
GLUT4 is highly expressed in adipose tissue and skeletal muscle, where it facilitates the diffusion of circulating 
glucose into muscle and fat cells along a concentration gradient (20, 21). GLUT4 translocation is stimulated by 
insulin or muscle contraction and helps regulate whole-body glucose homeostasis (22). GLUT4 translocation to 
the plasma membrane was elevated in the presence of CHI3L1, as shown by plasma membrane fractionation 
(Fig. 2A) and immunocytochemistry (Fig. 2B). Myc-GLUT4 levels in the plasma membrane were increased 
after CHI3L1 treatment (Fig. 2C) and this effect was suppressed in the presence of Compound C (Fig. 2D). The 
phosphoinositide 3-kinase (PI3K)/AKT signaling inhibitor LY294002 also suppressed CHI3L1-associated Myc-
GLUT4 levels (Fig. 2E). These results suggest that CHI3L1 stimulates GLUT4 translocation to the plasma 
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CHI3L1 increases intracellular Ca2+ via PAR2 and activated AMPK pathway
PAR2, also known as GPR11, is a G-protein-coupled receptor (GPCR) that stimulates the release of 
intracellular calcium, a second messenger frequently employed in signal transduction (23). PAR2 mediates 
CHI3L1-induced responses in skeletal muscle (8, 13). We measured intracellular calcium levels by staining L6 
cells with the calcium-binding dye Fluo-3 AM. CHI3L1 was associated with an increase in fluorescence 
intensity, an indicator of calcium concentration. We set out to confirm that CHI3L1 increased intracellular 
calcium levels by measuring fluorescence intensity in the presence of CHI3L1 in a calcium-free medium, and 
then by depleting the endoplasmic reticulum calcium with thapsigargin, a Ca2+-ATPase inhibitor. Fluorescence 
intensity increased in the presence of CHI3L1 in calcium-free media but remained unchanged with pretreatment 
with thapsigargin (Fig. 3A). Many cell surface receptors, including GPCRs, activate phospholipase C (PLC), 
which stimulates the release of calcium from the endoplasmic reticulum. Treatment with the PLC inhibitor 
U73122 blocked the induction of AMPK phosphorylation associated with CHI3L1 (Fig. 3B). The presence of 
U73122 also prevented CHI3L1-associated glucose uptake (Fig. 3C). Calcium/Calmodulin-dependent protein 
kinase kinase (CaMKK) , an upstream kinase of AMPK, requires calcium as a co-factor to induce AMPK 
phosphorylation. CaMKK inhibition with STO-609 blocked CHI3L1-associated AMPK phosphorylation (Fig. 
3D) and also blocked CHI3L1-associated glucose uptake (Fig. 3E). We then examined the expression patterns 
of different PARs to identify the specific CHI3L1 receptor involved in glucose homeostasis and found that 
PAR1, -2, -3, and -4 were all expressed in L6 cells (Fig. 3F). The PAR2 antagonist FSLLRY-NH2 blocked 
CHI3L1-associated AMPK phosphorylation (Fig. 3G) and also blocked CHI3L1-associated glucose uptake 
(Fig. 3H). These results indicate that CHI3L1 releases intracellular Ca2+ to activate the CaMKK/AMPK 
pathway via PAR2.
Effect of CHI3L1 on downstream targets of AMPK via AS160 and p38 MAPK pathway
AS160 is a Rab GTPase-activating protein. Phosphorylation of AS160 mediates the translocation of the glucose 
transporter GLUT4 to the plasma membrane in fat and muscle cells (24) and AS160 acts downstream of AMPK 
and AKT signaling during glucose uptake (25). CHI3L1 was associated with AS160 phosphorylation in L6 cells 
in a time- (Fig. 4A) and dose- (Fig. 4B) dependent manner. Inhibition of AMPK blocked the CHI3L1-
associated phosphorylation of AS160 (Fig. 4C), as did the siRNA-mediated knockdown of AMPKα2 (Fig. 4D). 
p38 MAPK functions downstream of AMPK phosphorylation during glucose uptake (26) to regulate GLUT4 
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cells while the knockdown of AMPKα2 by siRNA suppressed CHI3L1-associated p38 MAPK phosphorylation 
(Fig. 4E). Also, the p38 MAPK inhibitor SB203580 suppressed CHI3L1-associated glucose uptake (Fig. 4F). 
These results indicate that the p38 MAPK pathway participates in CHI3L1-mediated glucose uptake.
CHI3L1 activates AKT signaling to stimulate glucose uptake
We next explored the role of CHI3L1 in the PI3K/AKT signaling pathway, another key pathway mediating 
glucose uptake. CHI3L1 was associated with AKT phosphorylation in L6 cells in a time- (Fig. 5A) and dose- 
(Fig. 5B) dependent manner. The PAR2 antagonist FSLLRY-NH2 blocked this effect (Fig. 5C). The PI3K-
specific inhibitor LY294002 blocked CHI3L1-associated AKT phosphorylation (Fig. 5D) and also blocked 
CHI3L1-associated glucose uptake (Fig. 5E). Inhibition of PI3K/AKT signaling also suppressed CHI3L1-
associated AS160 phosphorylation (Fig. 5F), as did the siRNA-mediated knockdown of AKT2 (Fig. 5G). These 
results suggest that AKT mediates CHI3L1-associated glucose uptake, and CHI3L1 stimulates AS160 
phosphorylation via AKT signaling.
CHI3L1 activates AMPK phosphorylation in primary cultured myoblasts
To investigate the effects of CHI3L1 in a biologically relevant system, we used primary cultured myoblasts and 
found that CHI3L1 was associated with phosphorylation of AMPK and AKT, which increased in a time-
dependent manner (Fig. 6A). CHI3L1 was also observed to increased calcium levels in primary myoblasts (Fig. 
6B). The inhibition of CaMKK blocked CHI3L1-associated AMPK phosphorylation (Fig. 6C) and the 
inhibition of AMPK blocked CHI3L1-associated AS160 and p38 MAPK phosphorylation in primary myoblasts 
(Fig. 6D). These results indicate that CHI3L1 induces AMPK-mediated AS160 phosphorylation alongside AKT 
activation in primary cultured myoblasts, a biologically relevant effect.
Exercise elevates CHI3L1 expression in skeletal muscle cells
Exercise induces muscle contraction and AMPK activation (28). Muscle contraction alters the muscle secretome 
of myokines and metabolites that mediates crosstalk between the exercising muscle and distant target organs 
(29). EPS is used to induce muscle contraction in vitro and thereby mimic the effect of exercise (29). CHI3L1 
mRNA expression levels were increased after EPS in a time-dependent manner (Fig. 7A) alongside an increase 
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to exercise (Fig. 7C), and AMPK phosphorylation levels were higher in the muscle tissues of these mice than in 
controls (Fig. 7D). These results suggest that exercise elevates CHI3L1 expression both in vitro and in vivo.
Associations among plasma CHI3L1 levels, CHI3L1 genetic variants, and lymphocytic CHI3L1 mRNA 
expression in humans
We then set out to investigate whether CHI3L1 regulation of glucose metabolism is relevant in humans and 
thereby assessed potential associations among plasma CHI3L1 levels, CHI3L1 genetic variants, and 
lymphocytic CHI3L1 mRNA expression using two different datasets (clinical and community settings). Data 
from the clinical setting showed that old age was significantly associated with higher plasma levels of CHI3L1 
(young NGT group; 25–35 years; n = 20: 24.1 ± 2.3 ng/mL vs. old NGT group; 65–87 years, n = 20: 143.1 ± 
18.1 ng/mL, p < 0.0001) (Fig. 8A). Next, we compared plasma CHI3L1 levels according to diabetic status 
among old participants. Subjects with IGT and DM were grouped together and compared to the NGT group to 
assess the effect of impaired glucose metabolism. The old IGT + DM group showed significantly lower plasma 
CHI3L1 levels than those of the old NGT group (80.3 ± 7.6 ng/mL vs. 143.1 ± 18.1 ng/mL, p = 0.0004) (Fig. 
8B). Regarding the risk of DM in a community setting via the KoGES-ASAS study, the presence of the minor 
allele of rs10399805 (CHI3L1) was associated with a 15% lower risk of DM (HR: 0.85, 95% CI: 0.73 to 0.98, p 
= 0.023) (Fig. 8C), and 2.9-fold greater CHI3L1 mRNA expression in LCLs (p = 0.0048) (Fig. 8D). We also 
observed that rs10399805 was associated with lower GLUAUC levels (beta coefficient: -0.005, 95% CI: -0.009 
to -0.000, p = 0.039) (Fig. 8C). Finally, we tested whether CHI3L1 mRNA expression is associated with 
GLUAUC in a subset of KoGES-ASAS study participants (n = 134). No significant association between 
CHI3L1 mRNA expression in LCLs and GLUAUC was observed. However, physical activity modified this 
association, as physically active participants with higher CHI3L1 mRNA expression levels presented lower 
GLUAUC levels than physically inactive individuals with lower CHI3L1 mRNA expression levels (268.8 ± 8.5 
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DISCUSSION
Several studies have reported that CHI3L1 is associated with a range of inflammatory diseases, including 
asthma and autoimmune pathologies (30, 31). However, potential biological functions of CHI3L1 and its 
underlying molecular mechanisms in metabolic conditions remain unclear. In the present study, we 
hypothesized that CHI3L1 regulates glucose metabolism by activating multiple intracellular signaling pathway 
(Fig. 9). Our results indicate that CHI3L1 stimulated glucose uptake via AMPK in skeletal muscle cells as well 
as in primary cultured myoblasts; this was further supported by improved GTT following CHI3L1 injection in 
mice. Also, CHI3L1 was shown to induce p38 MAPK phosphorylation in L6 cells, an effect that was blocked 
by AMPK knockdown. p38 MAPK functions downstream of AMPK phosphorylation during glucose uptake 
(26). Based on the profound influence of the AMPK signaling pathway on glucose metabolism (32), we first 
assessed levels of AMPK pathway-associated proteins to uncover the underlying mechanisms involved in the 
influence of CHI3L1 on glucose uptake in skeletal muscle cells. AMPK is a heterotrimeric complex consisting 
of a catalytic subunit (α) and two regulatory subunits (β and γ) and is critical to growth regulation, cellular 
processes, and metabolism reprogramming (33). AMPK is activated by an increase in the AMP–ATP ratio in 
response to cellular stress, such as that exerted by skeletal muscles (34) during exercise. CaMKK, which 
responds to calcium flux, and liver kinase B1, which exists in a heterotrimeric complex with STRAD and 
MO25, have been identified as upstream kinases of AMPK (35-38). Glucose uptake, necessary for the 
maintenance of whole-body glucose homeostasis, involves the delivery of glucose to adipose tissue and skeletal 
muscle via glucose transporters (19). AMPK also participates in glucose uptake independent of insulin signaling 
(39). AMPK activation is induced by changes in cellular energy status, such as muscle contraction (40). In the 
present study, we found that CHI3L1 stimulated glucose uptake and GLUT4 translocation in an AMPK-
dependent manner in skeletal muscle cells. Our results indicate that CHI3L1 is secreted as a result of muscle 
contraction to increase glucose uptake via translocation of GLUT4 through the AMPK signaling pathway.
Along with the AMPK pathway and downstream p38 MAPK pathway, our results showed the AKT pathway 
was also involved in mediating CHI3L1-associated glucose uptake and GLUT4 translocation, as evidenced by 
phosphorylation of AS160. AKT is a serine/threonine-specific protein kinase that is an important signaling 
molecule in glucose homeostasis (41). We observed that PAR2, also called GPR11, is directly involved in 
CHI3L1-associated intracellular Ca2+ release and participates in downstream activation of the CaMKK/AMPK 
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receptors, with PAR2 as the primary CHI3L1 receptor in skeletal muscle (8, 13). In the present study, we 
demonstrated that PAR2 mediated CHI3L1-associated glucose homeostasis and that PAR1, -3, and -4 might 
also act as CHI3L1 receptors. The PAR2 receptor has been identified in almost all human organs (43), and 
CHI3L1 may thus be capable of influencing biological processes in almost all tissues, which inhibits its 
potential as a therapeutic drug. Our results are in line with previous findings that CHI3L1 treatment blocked 
TNFα-induced inflammation by inhibiting nuclear factor κB activation in skeletal muscle cells, a process that is 
mediated by PAR2 (13). Treatment of CHI3L1 in cultured human myoblasts was reported to stimulate the 
activation of p44/42, p38 MAPK, and AKT and enhance myoblast proliferation (8). Meanwhile, there is also 
possible involvement of other PAR dependent or even independent signaling pathways since PAR2 
antagonizing was not enough to fully attenuate the function of CHI3L1. Taken together, our findings indicate 
that CHI3L1 can enhance glucose uptake and GLUT4 translocation by stimulating AMPK and AKT pathways 
in skeletal muscle in vitro. This was supported by in vivo results in mice, which showed that CHI3L1 was 
secreted from muscle tissue into the bloodstream after exercise. We thereby surmise that CHI3L1 is a myokine 
that regulates glucose metabolism.
We further tested the hypothesis that the observed effects of CHI3L1 on glucose metabolism is relevant to 
humans. Accumulating studies have consistently reported that circulating levels of CHI3L1 are elevated in 
inflammatory diseases and related pathological conditions, such as asthma (30), atopy (17), and rheumatoid 
arthritis (18), suggesting it is a biomarker for inflammation. Conversely, reports on the association of blood 
CHI3L1 levels with metabolic conditions remain inconclusive. A few studies have shown that plasma levels of 
CHI3L1 are increased in obesity, insulin resistance, and type 2 diabetes (11, 12); however, no insulin sensitivity 
indexes were found to be significantly associated with plasma CHI3L1 levels in a Danish sample (44), 
suggesting that CHI3L1 is not directly involved in the development of type 2 diabetes. Besides, plasma CHI3L1 
level was not associated with insulin resistance in a human study using hyperinsulinemic-euglycemic clamp 
(45). A study by Park et al (46) conducted in Koreans showed higher CHI3L1 levels in diabetic patients 
compared to non-diabetic control, however, the very small sample size (only four diabetic patients for 
comparison) limits the generalization of the results. In contrast to previous findings (11, 12, 46), our results 
showed that the plasma levels of CHI3L1 were significantly lower in old participants with impaired glucose 
metabolism than those in normal control. CHI3L1 has been proposed to be an auto-protective factor that is 
induced upon demand to protect skeletal muscle cells from the negative impact of TNF, suggesting that 
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speculated that circulating levels of CHI3L1 may increase during low grade inflammation such as obesity and 
insulin resistance, but decrease progressively to reverse the metabolic derangement in type 2 diabetes. 
Alternatively, the ethnic background of the study population could partially explain this discrepancy. As a 
matter of fact, previous studies have shown that the genetic variants affecting CHI3L1 levels are inconsistent 
between ethnic groups (17, 47). The reduced CHI3L1 in type 2 diabetes shown in this study was further 
supported by a genetic association study on a Korean population. A genetic variant of CHI3L1 (rs10399805) 
located at its promoter region has been reported to increase the production of CHI3L1 in different populations 
(17, 18). A functional study conducted on Koreans reported that the genetic variant at CHI3L1 (rs10399805) 
was associated with significantly higher serum CHI3L1 levels, a 2.5-fold increase in CHI3L1 mRNA expression 
in peripheral blood cells, and increased risk of atopy in Koreans (17). In this study, a targeted genetic 
association study showed that the minor allele of rs10399805 (CHI3L1) was associated with higher CHI3L1 
mRNA expression in LCLs together with lower levels of glucose response area, supporting the hypothesis that 
plasma levels of CHI3L1 are reduced in type 2 diabetics in this population. Of note, our results also showed that 
physical activity synergistically interacts with CHI3L1 expression to mediate glucose responses in humans. 
Finally, our longitudinal genetic study revealed that the minor allele of rs10399805 (CHI3L1) was associated 
with a significantly lower risk for DM. Our results, together with those showing protective effects of CHI3L1 
on TNFα-induced insulin resistance and inflammation in vitro (13) led us to speculate that reduced levels of 
plasma CHI3L1 are associated with aberrant glucose metabolism in humans, which requires further 
confirmation in a larger and more diverse population.
In conclusion, our results indicate that CHI3L1 is a myokine that stimulates glucose uptake in skeletal muscles 
via the AMPK and AKT signaling pathways through PAR2, which is further relevant in glucose metabolism of 
humans. Further studies are needed to elucidate the biological functions of CHI3L1 and to better understand the 
relationship between CHI3L1 and glucose metabolism. Our results suggest CHI3L1 as a novel candidate for 
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FIGURE LEGENDS
Figure 1. CHI3L1 stimulates glucose uptake via AMPK in skeletal muscle cells. (A) L6 myotube cells were 
incubated with CHI3L1 (100 ng/mL) for the indicated times, followed by glucose uptake assay. (B) L6 
myotube cells were incubated with different concentrations of CHI3L1 for 1 h, followed by glucose 
uptake assay. (C) L6 myotube cells were incubated with CHI3L1 (100 ng/mL) for 1 h or insulin (100 
nM) for 15 min, followed by glucose uptake assay. (D) L6 cells were incubated with CHI3L1 (100 
ng/mL) for the indicated times. Cell lysates were analyzed by Western blot using antibodies against 
phospho-AMPKα (Thr172) and phospho-ACC (Ser79). (E) L6 cells were stimulated for 1 h with different 
concentrations of CHI3L1. Cell lysates were analyzed by Western blot using antibodies against 
phospho-AMPKα (Thr172) and phospho-ACC (Ser78). (D,E) p-AMPKα and p-ACC levels were 
quantified by densitometry and normalized to total AMPKα and ACC protein levels. (F) L6 cells were 
pretreated with the AMPK inhibitor compound C (30 µM) and then with CHI3L1 (100 ng/mL). Cell 
lysates were analyzed by Western blot using an antibody against phospho-AMPKα (Thr172). AMPKα 
served as a control. (G) L6 myotube cells were treated with CHI3L1 (100 ng/mL) for 1 h in the presence 
of compound C (30 µM), followed by glucose uptake assay. (H) L6 cells were transiently transfected 
with an AMPKα2 siRNA or a non-target siRNA for 48 h. Cell lysates were analyzed by Western blot 
using an antibody against AMPKα. β-actin served as a control. (I) L6 cells were transiently transfected 
with an AMPKα2 siRNA and non-target siRNA for 48 h. Differentiated cells were incubated with 
CHI3L1 (100 ng/mL) for 1 h, followed by glucose uptake assay. (A-E,G,I) Data are expressed as means 
± standard errors of the means (n = 3), and one-way ANOVA followed by Bonferroni post-test were 
used to compare between multiple groups. * p < 0.05, ** p < 0.01 as indicated. (J) Blood glucose levels 
and glucose response area during GTT in mice on high fat diet injected with either PBS (n = 8) or 
CHI3L1 (n = 8). Data are expressed as means ± standard errors of the means, and one-way ANOVA 
followed by Bonferroni post-test were used to compare between multiple groups. * p < 0.05, ** p < 0.01 
as indicated.
Figure 2. CHI3L1 stimulates GLUT4 translocation in skeletal muscle cells. (A) Fractionated plasma 
membranes from L6 cells were pretreated with CHI3L1 (100 ng/mL) or insulin (100 nM). Plasma 
membrane proteins were analyzed by Western blot using an antibody against GLUT4. The insulin 
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images (GLUT4, DAPI, and merge) of GLUT4-expressing cells treated with CHI3L1 for 1 h. Insulin 
(100 nM) was used as a positive control. Scale bars, 10 μm. (C) Confluent monolayers of L6 cells 
expressing Myc-GLUT4 were incubated with CHI3L1 (100 ng/mL) for 1 h. Cell surface expression of 
Myc-GLUT4 was detected using an antibody-coupled colorimetric absorbance assay. (D) L6 cells 
expressing Myc-GLUT4 were pretreated with compound C (30 µM) for 30 min and then incubated with 
CHI3L1 (100 ng/mL) for 1 h before assessing GLUT4 translocation. (E) L6 cells expressing Myc-
GLUT4 were pretreated with LY294002 (20 µM) for 30 min and then incubated with CHI3L1 (100 
ng/mL) for 1 h before assessing GLUT4 translocation. (C-E) Data are expressed as means ± standard 
errors of the means (n = 3), and one-way ANOVA followed by Bonferroni post-test were used to 
compare between multiple groups. * p < 0.05, ** p < 0.01 as indicated.
Figure 3. CHI3L1 increases intracellular Ca2+ and activates the AMPK pathway via PAR2. (A) L6 cells were 
preincubated with Fluo-3 AM (5 µM) for 30 min, and intracellular Ca2+ response was then measured 
using a confocal microscope after changing to calcium-free media and treating with CHI3L1. 
Alternatively, L6 cells were pretreated with the endoplasmic reticulum Ca2+-ATPase inhibitor 
thapsigargin (1 µM) and Ca2+ response was measured using a confocal microscope after treatment with 
CHI3L1. Scale bars, 100 μm. (B) L6 cells were pretreated with the PLC inhibitor U73122 (10 µM) and 
then with CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody against 
phospho-AMPKα (Thr172). AMPKα served as a control. (C) L6 myotube cells were treated with CHI3L1 
(100 ng/mL) for 1 h in the presence of U73122 (10 µM), followed by glucose uptake assay. (D) L6 cells 
were pretreated with the CaMKK inhibitor STO-609 (5 µM) and then with CHI3L1 (100 ng/mL). Cell 
lysates were analyzed by Western blot using an antibody against phospho-AMPKα (Thr172). AMPKα 
served as a control. (E) L6 myotube cells were treated with CHI3L1 (100 ng/mL) for 1 h in the presence 
of STO-609 (5 µM), followed by glucose uptake assay. (F) Total mRNA was prepared from L6 cells and 
RT-PCR was performed using specific primers against the PAR family members PAR1, -2, -3, and -4. 
PCR products were separated on 1.7% agarose gels and visualized under ultraviolet light with ACTB as 
a positive control. (G) L6 cells were pretreated with the selective PAR2 antagonist FSLLRY-NH2 (10 
µM) and then with CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody 
against phospho-AMPKα (Thr172). AMPKα served as a control. (H) L6 myotube cells were treated with 
CHI3L1 (100 ng/mL) for 1 h in the presence of FSLLRY-NH2 (10 µM), followed by glucose uptake 
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ANOVA followed by Bonferroni post-test were used to compare between multiple groups. * p < 0.05, 
** p < 0.01, *** p < 0.001 as indicated.
Figure 4. Effect of CHI3L1 on downstream targets of AMPK via AS160 and p38 MAPK pathway. (A) L6 cells 
were incubated with CHI3L1 (100 ng/mL) for the indicated times. Cell lysates were analyzed by 
Western blot using an antibody against phospho-AS160 (Thr642). (B) L6 cells were stimulated with 
different concentrations of CHI3L1 for 1 h. Cell lysates were analyzed by Western blot using an 
antibody against phospho-AS160 (Thr642). (A,B) p-AS160 levels were quantified by densitometry and 
normalized to total AS160 protein levels. (C) L6 cells were pretreated with compound C (30 µM) and 
then incubated with CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody 
against phospho-AS160 (Thr642). AS160 served as a control. (D) L6 cells were transiently transfected 
with an AMPKα2 siRNA for 48 h. Cell lysates were analyzed by Western blot using an antibody against 
phospho-AS160 (Thr642). AS160 served as a control. (E) L6 cells were transiently transfected with an 
AMPKα2 siRNA for 48 h. Cell lysates were analyzed by Western blot using an antibody against 
phospho-p38 MAPK. p38 MAPK served as a control. (F) L6 myotube cells were treated with CHI3L1 
(100 ng/mL) for 1 h in the presence of the p38 MAPK inhibitor SB203580 (10 µM), followed by 
glucose uptake assay. (A,B,F) Data are expressed as means ± standard errors of the means (n = 3), and 
one-way ANOVA followed by Bonferroni post-test were used to compare between multiple groups. * p 
< 0.05, ** p < 0.01, *** p < 0.001 as indicated.
Figure 5. CHI3L1 activates AKT signaling to stimulate glucose uptake. (A) L6 cells were incubated with 
CHI3L1 (100 ng/mL) for the indicated times. Cell lysates were analyzed by Western blot using an 
antibody against phospho-AKT (Ser473). (B) L6 cells were stimulated for 1 h with different 
concentrations of CHI3L1. Cell lysates were analyzed by Western blot using an antibody against 
phospho-AKT (Ser473). (A,B) p-AKT levels were quantified by densitometry and normalized to total 
AKT protein levels. (C) L6 cells were pretreated with the selective PAR2 antagonist FSLLRY-NH2 (10 
µM) and then with CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody 
against phospho-AKT (Ser473). AKT served as a control. (D) L6 cells were pretreated with the PI3K 
inhibitor LY294002 (20 µM) and then with CHI3L1 (100 ng/mL). Cell lysates were analyzed by 
Western blot using an antibody against phospho-AKT (Ser473). AKT served as a control. (E) L6 
myotube cells were treated with CHI3L1 (100 ng/mL) for 1 h in the presence of LY294002 (20 µM), 
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CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody against phospho-
AS160 (Thr642). AS160 served as a control. (G) L6 cells were transiently transfected with an AKT2 
siRNA for 48 h. Cell lysates were analyzed by Western blot using an antibody against phospho-AS160 
(Thr642). AS160 served as a control. (A,B,E) Data are expressed as means ± standard errors of the means 
(n = 3), and one-way ANOVA followed by Bonferroni post-test were used to compare between multiple 
groups. n.s; not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 as indicated.
Figure 6. CHI3L1 activates AMPK phosphorylation in primary cultured myoblasts. (A) Myoblasts were 
stimulated with CHI3L1 for the indicated times. Cell lysates were analyzed by Western blot using 
antibodies against phospho-AMPKα (Thr172) and phospho-AKT (Ser473). p-AMPKα and p-AKT levels 
were quantified by densitometry and normalized to total AMPKα and AKT protein levels. Data are 
expressed as means ± standard errors of the means (n = 3), and one-way ANOVA followed by 
Bonferroni post-test were used to compare between multiple groups. * p < 0.05, ** p < 0.01, *** p < 
0.001 as indicated. (B) For Ca2+ detection, myoblasts were preincubated with Fluo-3 AM (5 μM) for 30 
min. Ca2+ response was measured using a confocal microscope after treatment with CHI3L1. Scale bars, 
100 μm. (C) Myoblasts were pretreated with the CaMKK inhibitor STO-609 (5 µM) and then with 
CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using an antibody against phospho-
AMPKα (Thr172). AMPKα served as a control. (D) Myoblasts were pretreated with compound C (30 
µM) and then with CHI3L1 (100 ng/mL). Cell lysates were analyzed by Western blot using antibodies 
against phospho-AS160 (Thr642) and phospho-p38 MAPK. AS160 and p38 MAPK served as controls.
Figure 7. Exercise elevates CHI3L1 expression in skeletal muscle. (A) Total mRNA was prepared from 
differentiated L6 myotube cells after EPS, and RT-PCR was performed using CHI3L1-specific primers. 
PCR products were separated on 1.7% agarose gels and visualized under ultraviolet light with ACTB as 
a positive control. (B) L6 cells were subjected to several rounds of EPS. Lysates were analyzed by 
Western blot using an antibody against phospho-AMPKα (Thr172). p-AMPKα levels were quantified by 
densitometry and normalized to total AMPKα protein levels. Data are expressed as means ± standard 
errors of the means (n = 3), and one-way ANOVA followed by Bonferroni post-test were used to 
compare between multiple groups. * p < 0.05 as indicated. (C) Mice were sacrificed after exercise and 
levels of circulating CHI3L1 were measured by ELISA. Data are expressed as means ± standard errors 
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as indicated. (D) Muscle tissues from the same animals were lysed for Western blot analysis using an 
antibody against phospho-AMPKα (Thr172). AMPKα served as a control.
Figure 8. Associations among plasma CHI3L1 levels, CHI3L1 genetic variants, and lymphocytic CHI31L 
mRNA expression. (A) Plasma CHI3L1 levels of young NGT (n = 20) and old NGT (n = 20). (B) 
Plasma CHI3L1 levels of old NGT (n = 20) and old IGF+DM (n = 40) groups. (C) Genetic association 
of CHI3L1 with risk for DM and diabetic traits. Values are presented as HR or beta coefficient with 95% 
CI. P-values were obtained from Cox proportional hazards regression or multiple linear regression 
analysis after adjustment for sex, age, area, education level, smoking, drinking, hypertension, and 
metabolic equivalent. (D) Comparison of relative CHI3L1 mRNA expression in LCLs (fold change) 
according to CHI3L1 genotype, analyzed using Reverse transcription quantitative PCR. (E) Comparison 
of GLUAUC levels between physically inactive with lower CHI3L1 mRNA expression and physically 
active with higher CHI3L1 mRNA expression. (A,B,D,E) Data are expressed as means ± standard errors 
of the means, and Student’s t-test were used to compare between groups. * p < 0.05, ** p < 0.01, *** p 
< 0.001 as indicated.
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